Americans waiting for refreshed cancer-screening advice are still waiting on process. On Sept. 17, HHS announced eight new USPSTF members — the first time the task force includes specialists beyond its traditional prevention and primary-care core — with pediatric hematologist-oncologist Seth J. Corey named chair, Healio reported. Appointees include cardiologists, a radiologist, a health economist, and others joining eight remaining members.

The rebuild follows months of turmoil. The task force has not met since March 2025 and has not issued guidance since July 2025. In May, HHS Secretary Robert F. Kennedy Jr.’s department removed the prior chair and vice chair, saying they were “inappropriately appointed.” AMA and ACP leaders warned that departing from a primary-care-heavy roster could weaken trust among clinicians who deliver mammograms, colon cancer tests, and other preventive services every day.

Avalere Health and other policy shops have flagged canceled meetings as a practical problem: without convened reviews, A and B recommendations that shape insurance coverage for screenings do not advance. USPSTF’s public A/B list remains the reference clinicians use, but it is aging while the new panel finds its footing. For patients, the stake is whether tomorrow’s colonoscopy or lung-cancer CT guidance will still match what insurers pay for without new evidence reviews. Until new recommendations publish, clinicians should keep using the existing A and B grades that still govern many insurance mandates. Patients due for mammograms, colonoscopies, or lung CT scans should not delay care solely because the task force roster changed.

What we know:
Eight new USPSTF members were seated in mid-September; the panel’s meeting and guidance cadence has been broken since 2025.

What we don’t:
When the reconstituted task force will next meet or issue cancer-screening updates.